AU2003215524A1 - Pharmaceutical compositions comprising mannose binding lectin - Google Patents

Pharmaceutical compositions comprising mannose binding lectin

Info

Publication number
AU2003215524A1
AU2003215524A1 AU2003215524A AU2003215524A AU2003215524A1 AU 2003215524 A1 AU2003215524 A1 AU 2003215524A1 AU 2003215524 A AU2003215524 A AU 2003215524A AU 2003215524 A AU2003215524 A AU 2003215524A AU 2003215524 A1 AU2003215524 A1 AU 2003215524A1
Authority
AU
Australia
Prior art keywords
mbl
pharmaceutical compositions
binding lectin
compositions
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003215524A
Other languages
English (en)
Inventor
Leif Kongerslev
Jesper Lund Larsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NatImmune AS
Original Assignee
NatImmune AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NatImmune AS filed Critical NatImmune AS
Publication of AU2003215524A1 publication Critical patent/AU2003215524A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003215524A 2002-03-15 2003-03-14 Pharmaceutical compositions comprising mannose binding lectin Abandoned AU2003215524A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200414 2002-03-15
DKPA200200414 2002-03-15
PCT/DK2003/000179 WO2003077937A1 (en) 2002-03-15 2003-03-14 Pharmaceutical compositions comprising mannose binding lectin

Publications (1)

Publication Number Publication Date
AU2003215524A1 true AU2003215524A1 (en) 2003-09-29

Family

ID=27763313

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003215524A Abandoned AU2003215524A1 (en) 2002-03-15 2003-03-14 Pharmaceutical compositions comprising mannose binding lectin

Country Status (11)

Country Link
US (1) US7462596B2 (cg-RX-API-DMAC7.html)
EP (1) EP1344533B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005526084A (cg-RX-API-DMAC7.html)
CN (1) CN1652813A (cg-RX-API-DMAC7.html)
AT (1) ATE337014T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003215524A1 (cg-RX-API-DMAC7.html)
DE (1) DE60307701T2 (cg-RX-API-DMAC7.html)
DK (1) DK1344533T3 (cg-RX-API-DMAC7.html)
ES (1) ES2271515T3 (cg-RX-API-DMAC7.html)
PT (1) PT1344533E (cg-RX-API-DMAC7.html)
WO (1) WO2003077937A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5562510B2 (ja) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
GB0222014D0 (en) * 2002-09-23 2002-10-30 Leuven K U Res & Dev Mannan-binding lectin
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
AU2004290862B2 (en) 2003-11-20 2010-06-03 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US7335633B2 (en) * 2004-01-12 2008-02-26 Cornell Research Foundation, Inc. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
EP1618887A1 (en) * 2004-07-12 2006-01-25 UMC Utrecht Holding B.V. Clearance of polyols from the body
WO2006024631A2 (en) 2004-08-31 2006-03-09 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
JP5175103B2 (ja) 2004-11-12 2013-04-03 ノヴォ ノルディスク アー／エス 安定なペプチド製剤
KR100770362B1 (ko) * 2004-12-30 2007-10-26 (주)두비엘 분무건조 고분자형 콜렉틴족 단백질 및 그의 제조방법
EP1874333A2 (en) * 2005-04-11 2008-01-09 Natimmune A/S Mannan-binding lectin (mbl) in the treatment of immunocompromised conditions asssociated with cancer
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
WO2007102736A2 (en) * 2006-03-08 2007-09-13 Universitair Medisch Centrum Utrecht Interfering in activation of an immune cell by influencing interaction of lair and collagen.
CA2736563C (en) * 2007-09-10 2016-01-26 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
CN102712687A (zh) 2009-07-17 2012-10-03 丹麦国家医院 作为补体激活的抑制剂的masp同种型
US9150631B2 (en) 2010-01-19 2015-10-06 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
RU2591823C2 (ru) 2010-03-19 2016-07-20 Бостон Байомедикал, Инк. Новые способы направленного воздействия на раковые стволовые клетки
EP3081937B1 (en) 2011-07-18 2019-11-13 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
US9632085B2 (en) 2012-02-29 2017-04-25 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
DK2861246T3 (en) * 2012-06-18 2021-04-26 Omeros Corp Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders
EP2976642A4 (en) 2013-03-15 2016-09-21 Harvard College METHOD AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR RECORDING OF A TARGET UNIT
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
JP6649250B2 (ja) 2013-05-21 2020-02-19 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたヘム結合性構成物およびその使用
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
EP3763378A1 (en) 2015-08-06 2021-01-13 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
EP4360651A3 (en) 2017-08-24 2024-07-17 Novo Nordisk A/S Glp-1 compositions and uses thereof
CN110755601B (zh) * 2019-10-31 2023-06-23 云南康洲生物科技有限公司 一种治疗hiv/aids免疫重建缺陷的芸豆凝集素植物药组合物和制备方法及其应用
KR20220143036A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형
AU2021466116A1 (en) * 2021-10-01 2024-04-11 Faculty Of Chemistry Carbohydrate binding polypeptide of savalia savaglia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE336504T1 (de) * 1998-06-10 2006-09-15 Statens Seruminstitut Reinigungsverfahren zur herstellng von mannan bindendem lectin (mbl) und mbl enthaltende medizinische zubereitung
US6429192B1 (en) * 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
US6297024B1 (en) * 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
CA2372128A1 (en) * 1999-05-14 2000-11-23 Steffen Thiel Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals
US7211396B2 (en) * 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin

Also Published As

Publication number Publication date
DK1344533T3 (da) 2007-01-08
CN1652813A (zh) 2005-08-10
DE60307701T2 (de) 2007-10-11
EP1344533B1 (en) 2006-08-23
ATE337014T1 (de) 2006-09-15
DE60307701D1 (de) 2006-10-05
US20040006009A1 (en) 2004-01-08
WO2003077937A1 (en) 2003-09-25
PT1344533E (pt) 2007-01-31
US7462596B2 (en) 2008-12-09
ES2271515T3 (es) 2007-04-16
EP1344533A1 (en) 2003-09-17
JP2005526084A (ja) 2005-09-02

Similar Documents

Publication Publication Date Title
AU2003215524A1 (en) Pharmaceutical compositions comprising mannose binding lectin
IL203923A (en) Benzamide compounds, pharmaceutical compositions comprising them, use thereof in the preparation of medicaments and as medicaments and processes for the preparation of such compounds
HK81397A (en) Pharmaceutical compositions containing benzenesulphonamides
HUP0401241A3 (en) Novel cyclohexyl sulphones, process for their preparation and pharmaceutical compositions containing them
HUP0303148A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing the compounds and processes for their preparation
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
CA2431565A1 (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
CA2534798A1 (en) Thiazole derivatives as cannabinoid receptor modulators
HUP0400246A3 (en) 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
IL204947A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them
CA2338600A1 (en) Novel thiazolopyrimidine compounds
HUP0103063A3 (en) Novel 2h-pyridazin-3-one derivatives, process for their preparation, their use and pharmaceutical compositions containing them
IL171914A0 (en) Variants of il-18bp, their preparation and pharmaceutical compositions containing them
CA2388910A1 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
AU2002348829A1 (en) Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO2003020963A3 (en) Proteins in type 2 diabetes
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
WO2003050067A3 (fr) Analogues de la vitamine d
HUP0401082A3 (en) Substituted 4-aminocyclohexanols, process for their preparation and pharmaceutical compositions containing them
WO2000072833A3 (de) Pharmazeutische zubereitungen zur hemmung von spimgomyelinase
WO2004031222A3 (en) Dna vaccine encoding at least two nonstructural early proteins of papillomavirus
MXPA03010259A (es) Nuevos derivados de 5-tio-ss-d-xilopiranosida, procedimiento de preparacion, composiciones farmaceuticas que los contienen y el uso terapeutico de los mismos.
HUP0401906A3 (en) Novel cathepsin s inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2004110367A3 (en) Sdr proteins from staphylococcus capitis and their use in preventing and treating infections
HUP0401038A3 (en) Piperazinylcarbonylquinolines and -isoquinolines, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase